YuGuo Bio Submits IPO Prospectus Featuring China's First NMPA-Approved Fully Automated Nucleic Acid Extraction and Library Preparation System – MetaLab 1.68
hugo biotech
Provider of Microbial Sequencing and Microbial Genome Big Data Analysis Services
With the intensifying aging of China’s population, rising per capita healthcare expenditures, and technological advancements, China’s in vitro diagnostics (IVD) market is expected to sustain rapid growth over the long term, with demand for services and equipment poised to surge.
High-Throughput SequencingDespite being applied in clinical settings for over a decade, mature automated and routine testing methods have yet to be established; current approaches have not achieved full-process automation, byhugo biotech(hereinafter referred to as “Hugo Biotech”) independently developedMetaLab 1·68 Automated Nucleic Acid Extraction and Library Preparation SystemIt is the first device in China approved by the National Medical Products Administration (NMPA) that can achieveEnd-to-End AutomationThe verification of equipment for extraction and library preparation communication has significantly enhanced the automation level of high-throughput sequencing, filling a market gap. The global gene sequencing market is projected to reach $24.58 billion by 2030, with an expected compound annual growth rate (CAGR) of 18.2%, indicating substantial market potential.
On Thursday, September 12, at 19:30, the 94th session of VCBeat New Product Showcase will feature Gao Peng, Senior Product Manager at Hugo Biotech, who will presentOne-Stop “Sample In, Library Out” Fully Automated Nucleic Acid Extraction and Library Preparation InstrumentProduct Introduction.
MetaLab1·68 Automated Nucleic Acid Extraction and Library Preparation Workstation
Metalab 1·68 Automated Nucleic Acid Extraction and Library Preparation InstrumentThis innovative device, independently developed by Hugo Biotech, is designed for sample pre-processing in mNGS. It automatically completes nucleic acid extraction and library preparation, while also being compatible with qPCR system setup. By enabling full-process automation, it allows high-throughput sequencing experiments to be completed with just one technician performing a single-step operation, significantly lowering the technical barrier for users.As the first fully automated nucleic acid extraction and library preparation instrument approved in China, it is also at the forefront internationally.
This product isWorld’s First Fully Automated Nucleic Acid Extraction and Library Preparation Platform with Multiple Independent Chambers and Negative Pressure Control, truly achievingUnattended, eliminating the need for manual reagent loading and significantly accelerating the adoption of NGS.
Covering an area of 1.68 square metersachieving the ideal "sample-in, library-out" workflow. MetaLab 1·68 fully simulates a PCR laboratory, utilizingIndependent Three-Chamber Design, gradient negative pressure, automatic PCR film sealing, protective covers for reagents and consumables, and dry-wet separation of waste liquids provide multiple layers of contamination protection, while ensuring the safety of both personnel and samples.
While improving personnel efficiency, it reduced training frequency and costs., reducing process management. It is applicable to fields such as infectious pathogen detection, oncology, genetic diseases, and reproductive testing, accelerating the development of high-throughput sequencing technology platforms within hospitals and facilitating the translation of scientific achievements into clinical applications.
In addition, inClinical DiagnosisIn China, MetaLab 1·68 demonstrates high efficiency and accuracy in automated nucleic acid extraction and library preparation.Helps improve the efficiency of disease detection and screening, providing a more reliable basis for clinical decision-making.Meanwhile, by integrating pathogen metagenomic data, pathogen viability assay data, and pathogen transmissibility data across various scenarios, an intelligent pathogen sensing and early warning system can be constructed for different contexts, thereby providing a basis for pathogen prevention and control, risk assessment, guided interventions, and decision-making.
Scan the QR code on the poster to add our assistant and reserve your spot for the live broadcast.
Gao Peng
Senior Product Manager, Hugo Biotech
M.S. in Pathogen Biology from Guangdong Pharmaceutical University, with over 10 years of experience in the field and promotion of high-throughput sequencing. Previously responsible for the promotion, technical support, and management of high-throughput sequencing products at Illumina and MGI Tech.
About Hugo Biotech
Hugo Biotech, established in 2017, is rooted in China’s precision medicine industry for infectious diseases and is committed to creating a comprehensive product portfolio for pathogenic microorganism analysis. As one of the earliest enterprises in China to promote the translational application of cell-free mNGS, the company also participated in and completed the first batch of National Key R&D Programs under the “13th Five-Year Plan” initiated by the Ministry of Science and Technology. In 2021, Hugo Biotech became a member of the expert group serving as the national technical focal point for standardization of medical high-throughput sequencing, contributing to the development and revision of relevant standards in this specialized field. In 2022, it was listed among Fortune China’s Most Socially Influential Startups, and in 2023, it earned the distinction of being named one of the Top 500 Hidden Unicorns.
With nearly 50 patent applications and grants, over 100 software copyrights, and more than 100 SCI-indexed papers published in prestigious journals such as Nature, Nature Communications, PNAS, and EMI, the company has been recognized as a National High-Tech Enterprise and a National Specialized, Refined, Differential, and Innovative SME. It has been designated as the “Open Laboratory for Intelligent Sequencing Scenarios” within the Beijing National New Generation Artificial Intelligence Innovation Development Pilot Zone and has established a joint pan-genome laboratory with universities. By building China’s largest pathogenic microorganism pan-genome database and collaborating with institutions such as the Shanghai Institute of Laboratory Medicine, it supports precise pathogen diagnosis for major human diseases, infectious diseases, and refractory conditions, thereby advancing experimental medicine in China.
Leveraging the company’s achievement in transforming scientific outcomes into commercial products, we have established localized product centers in more than ten cities across China, with our business coverage extending to over 150 cities nationwide and our products applied to more than 350,000 samples. We strive to provide precise pathogen data analysis to clearly identify the causes of infection for a greater number of patients in the shortest possible time.
VCBeat New Product Review
“Artery New Product Showcase” is a live-streaming series dedicated to supporting healthcare companies in launching innovative products. The program’s mission is to facilitate the milestone launch of every innovative medical product. Companies with plans to release innovative medical products or achieve significant milestones and wish to participate in the “Artery New Product Showcase” are invited to contact our assistant for inquiries.
Method 1: Watch the Live Stream via Mini Program
Scan the QR code below to contact the assistant and schedule a live stream (if already added, please proactively reach out to the assistant)
Method 2: Watch the live stream on the VCBeat app for a chance to win lucky prizes
Scan the QR code below to download the VCBeat app and register to watch the live stream.
Send a screenshot of the live stream to the assistant to enter the lucky draw for a chance to win a [15-day trial membership of VBInsight].
